Principales publications

 

Quesnel B.
Tumor dormancy: long-term survival in a hostile environment.
Adv Exp Med Biol 2013;734:181-200.


Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, Tricot S, Daudignon A, Galiegue-Zouitina S, Soenen V, Theisen O, Grardel N, Nibourel O, Roche-Lestienne C, Quesnel B, Duthilleul P, Preudhomme C, Leleu X.

MYD88 L265P mutation in Waldenstrom macroglobulinemia.
Blood 2013;121:4504-4511.


Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Lepretre F, Renneville A, Cheok M, Soulier J, Dombret H, Preudhomme C.
Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia.

Am J Hematol 2013;88:306-311.


Berthon C, Fontenay M, Corm S, Briche I, Allorge D, Hennart B, Lhermitte M, Quesnel B.
Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification.
Leuk Res 2013;37:573-579.


Abdelhamid E, Figeac M, Renneville A, Quief S, Villenet C, Boyer T, Nibourel O, Coiteux V, Cassinat B, Lippert E, Helevaut N, Soua Z, Preudhomme C.
Quantification of JAK2V617F mutation by next-generation sequencing technology.
Am J Hematol 2013;88:536-537.


Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton S, Revel T, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Leukemia 2012;26:1247-1254.

 

Peyrouze P, Guihard S, Grardel N, Berthon C, Pottier N, Pigneux A, Cahn JY, Bene MC, Lheritier V, Delabesse E, Macintyre E, Thomas X, Dombret H, Ifrah N, Cheok M.
Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study.
Br J Haematol 2012;159:599-602.

 

Joha S, Nugues AL, Hetuin D, Berthon C, Dezitter X, Dauphin V, Mahon FX, Roche-Lestienne C, Preudhomme C, Quesnel B, Idziorek T.
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Oncogene 2012;31:1419-1430.

 

Guihard S, Peyrouze P, Cheok MH.
Pharmacogenomic considerations of xenograft mouse models of acute leukemia.
Pharmacogenomics 2012;13:1759-1772.

 

Cornet E, Dumezy F, Roumier C, Lepelley P, Jouy N, Philippe N, Renneville A, Berthon C, Nelken B, Quesnel B, Preudhomme C.
Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis.
Leuk Res 2012;36:1330-1333.

 

Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, Legros L, Nicolini F, Rousselot P, Gardembas M, Helevaut N, Frimat C, Mahon FX, Guilhot F, Preudhomme C.
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.
Leukemia 2011;25:1661-1664.

 

Kuranda K, Berthon C, Lepretre F, Polakowska R, Jouy N, Quesnel B.
Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitor-like state.
J Cell Biochem 2011;112:1277-1285.

 

Grellier E, Lecolle K, Rogee S, Couturier C, D’Halluin JC, Hong SS, Fender P, Boulanger P, Quesnel B, Colin M.
A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors.
Mol Cancer 2011;10:105.

 

Diouf B, Cheng Q, Krynetskaia NF, Yang W, Cheok M, Pei D, Fan Y, Cheng C, Krynetskiy EY, Geng H, Chen S, Thierfelder WE, Mullighan CG, Downing JR, Hsieh P, Pui CH, Relling MV, Evans WE.
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells.
Nat Med 2011;17:1298-1303.

 

Delestre L, Berthon C, Quesnel B, Figeac M, Kerckaert JP, Galiegue-Zouitina S, Shelley CS.
Repression of the RHOH gene by JunD.
Biochem J 2011;437:75-88.

 

Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L.
Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study.
Blood 2011;118:4331-4337.

 

Boissel N, Nibourel O, Renneville A, Huchette P, Dombret H, Preudhomme C. D
Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Blood 2011;117:3696-3697.

 

Rogee S, Grellier E, Bernard C, Jouy N, Loyens A, Beauvillain JC, Fender P, Corjon S, Hong SS, Boulanger P, Quesnel B, D’Halluin JC, Colin M.
Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response.
Gene Ther 2010;17:880-891.

 

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
N Engl J Med 2010;363:2511-2521.

 

Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C.
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
Blood 2010;116:1132-1135.

 

Kuranda K, Berthon C, Dupont C, Wolowiec D, Leleu X, Polakowska R, Jouy N, Quesnel B.
A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
Exp Hematol 2010;38:124-131.

 

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C.
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
J Clin Oncol 2010;28:3717-3723.

 

Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N, Hetuin D, Quesnel B.
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.
Cancer Immunol Immunother 2010;59:1839-1849.

 

Terriou L, Ben Abdelali R, Roumier C, Lhermitte L, de Vos J, Cornillet P, Nibourel O, Beldjord K, Dombret H, Leverger G, Asnafi V, Preudhomme C, Macintyre E.
C/EBPA methylation is common in T-ALL but not in M0 AML.
Blood 2009;113:1864-1866; author reply 1866.

 

Roumier C, Cheok MH.
Pharmacogenomics in acute myeloid leukemia.
Pharmacogenomics 2009;10:1839-1851.

 

Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, Philippe N, Thomas X, Dombret H, Preudhomme C.
Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
Cancer 2009;115:3719-3727.

 

Renneville A, Boissel N, Gachard N, Naguib D, Bastard C, de Botton S, Nibourel O, Pautas C, Reman O, Thomas X, Gardin C, Terre C, Castaigne S, Preudhomme C, Dombret H.
The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.
Blood 2009;113:5090-5093.

 

Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N, Dhedin N, Andre JM, Cornillet-Lefebvre P, Baruchel A, Mozziconacci MJ, Sobol H.
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.
Blood 2009;113:5583-5587.

 

Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, Dupont C, Briche I, Quesnel B.
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-gamma.
Leuk Res 2009;33:490-494.

 

Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D.
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
J Clin Oncol 2009;27:5195-5201.

 

Cheok MH, Pottier N, Kager L, Evans WE.
Pharmacogenetics in acute lymphoblastic leukemia.
Semin Hematol 2009;46:39-51.

 

Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Lai JL, Nicolini FE, Preudhomme C.
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Blood 2008;111:3735-3741.

 

Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C.
Cooperating gene mutations in acute myeloid leukemia: a review of the literature.
Leukemia 2008;22:915-931.

 

Pottier N, Yang W, Assem M, Panetta JC, Pei D, Paugh SW, Cheng C, Den Boer ML, Relling MV, Pieters R, Evans WE, Cheok MH.
The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
J Natl Cancer Inst 2008;100:1792-1803.

 

Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N, Preudhomme C, Quesnel B.
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
Leukemia 2008;22:791-799.

 

Galiegue-Zouitina S, Delestre L, Dupont C, Troussard X, Shelley CS.
Underexpression of RhoH in Hairy Cell Leukemia.
Cancer Res 2008;68:4531-4540.

 

Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, Lai JL, Rose C, Preudhomme C.
JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
2008;22:1454-1455.

 

Biggio V, Renneville A, Nibourel O, Philippe N, Terriou L, Roumier C, Amouyel P, Cottel D, Castaigne S, Dombret H, Thomas X, Fenaux P, Preudhomme C.
Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.
Leukemia 2008;22:655-657.

 

Saudemont A, Hamrouni A, Marchetti P, Liu J, Jouy N, Hetuin D, Colucci F, Quesnel B.
Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1.
Cancer Res 2007;67:4491-4498.

 

Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A, Quesnel B.
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.
Blood 2007;110:296-304.